Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
Richard BuusIvana SestakRalf KronenwettSean FerreeCatherine A SchnabelFrederick L BaehnerElizabeth A MallonJack M CuzickMitchell DowsettPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
In contrast to common understanding, RSs are determined more strongly by estrogen-related features and only weakly by proliferation markers. However, the EP, BCI, and particularly ROR scores are determined largely by proliferative features. These relationships help to explain the differences in the prognostic performance of the tests.